| dc.contributor.author |
Gaikwad, Anil Bhanudas |
|
| dc.date.accessioned |
2023-12-20T09:27:39Z |
|
| dc.date.available |
2023-12-20T09:27:39Z |
|
| dc.date.issued |
2019-03 |
|
| dc.identifier.uri |
https://www.sciencedirect.com/science/article/abs/pii/S0024320519301171 |
|
| dc.identifier.uri |
http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13461 |
|
| dc.description.abstract |
Renin-angiotensin system (RAS) and natriuretic peptides system (NPS) perturbations govern the development of diabetic nephropathy (DN). Hence, in search of a novel therapy against DN, present study targeted both, NPS and RAS simultaneously using a neprilysin inhibitor (NEPi) in combination with either angiotensin receptor blocker (ARB) or angiotensin-converting enzyme 2 (ACE2) activator. |
en_US |
| dc.language.iso |
en |
en_US |
| dc.publisher |
Elsevier |
en_US |
| dc.subject |
Pharmacy |
en_US |
| dc.subject |
Diabetic nephropathy |
en_US |
| dc.subject |
Renin-angiotensin system (RAS) |
en_US |
| dc.subject |
Diabetic nephropathy (DN) |
en_US |
| dc.title |
Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy |
en_US |
| dc.type |
Article |
en_US |